The impact of a heart failure management protocol based on a hospital-community pharmacist collaboration.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Junichi Terashima, Takahiro Kambara, Eisei Hori, Masahiro Fukatsu, Yukina Ichiki, Eri Oki, Risako Koketsu, Rika Taguchi, Suzuka Mii, Ryoka Hiro, Teruhiro Sakaguchi, Hiroyuki Osanai, Tomoya Tachi, Tadashi Suzuki
{"title":"The impact of a heart failure management protocol based on a hospital-community pharmacist collaboration.","authors":"Junichi Terashima, Takahiro Kambara, Eisei Hori, Masahiro Fukatsu, Yukina Ichiki, Eri Oki, Risako Koketsu, Rika Taguchi, Suzuka Mii, Ryoka Hiro, Teruhiro Sakaguchi, Hiroyuki Osanai, Tomoya Tachi, Tadashi Suzuki","doi":"10.1186/s40780-025-00426-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure has a high readmission rate, but interventions by multiple professionals are effective. Although there is growing interest in the management of heart failure by community pharmacists in Japan, no effective method has been developed. We created and verified the effectiveness of a novel heart failure management protocol that community pharmacists could utilize.</p><p><strong>Methods: </strong>This study included 68 patients (80.8 ± 11.8 years; male, 60.3%) diagnosed with heart failure who was admitted to our hospital between March 2022 and September 2023. A protocol was developed for the regular follow-up of patients and responses to exacerbations, in collaboration with pharmacists. Patients who were able to receive follow-up from community pharmacists were included in the intervention group, otherwise they were included in the control group. The primary endpoint was readmission, and the secondary endpoint was a composite of readmission, all-cause death, hospitalization, and dialysis due to dehydration or renal dysfunction.</p><p><strong>Results: </strong>The Kaplan-Meier analysis (p = 0.021) and Cox model (hazard ratio: 0.28, 95% confidence interval: 0.09-0.89, p = 0.031) revealed a significantly lower incidence of heart failure readmission within 360 days in the intervention group than in the control group.</p><p><strong>Conclusions: </strong>The implementation of a heart failure management protocol that provides clear guidance on appropriate patient management enabled pharmacists to effectively reduce the likelihood of adverse events, such as heart failure readmission.</p><p><strong>The registration number: </strong>UMIN000046750, registered on February 1, 2022.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"19"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905601/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-025-00426-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Heart failure has a high readmission rate, but interventions by multiple professionals are effective. Although there is growing interest in the management of heart failure by community pharmacists in Japan, no effective method has been developed. We created and verified the effectiveness of a novel heart failure management protocol that community pharmacists could utilize.

Methods: This study included 68 patients (80.8 ± 11.8 years; male, 60.3%) diagnosed with heart failure who was admitted to our hospital between March 2022 and September 2023. A protocol was developed for the regular follow-up of patients and responses to exacerbations, in collaboration with pharmacists. Patients who were able to receive follow-up from community pharmacists were included in the intervention group, otherwise they were included in the control group. The primary endpoint was readmission, and the secondary endpoint was a composite of readmission, all-cause death, hospitalization, and dialysis due to dehydration or renal dysfunction.

Results: The Kaplan-Meier analysis (p = 0.021) and Cox model (hazard ratio: 0.28, 95% confidence interval: 0.09-0.89, p = 0.031) revealed a significantly lower incidence of heart failure readmission within 360 days in the intervention group than in the control group.

Conclusions: The implementation of a heart failure management protocol that provides clear guidance on appropriate patient management enabled pharmacists to effectively reduce the likelihood of adverse events, such as heart failure readmission.

The registration number: UMIN000046750, registered on February 1, 2022.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信